Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections
Abstract Introduction Stenotrophomonas maltophilia is notable for its rising incidence and multidrug resistance, which complicates treatment. As a result of insufficient clinical studies, the 2024 Infectious Diseases Society of America (IDSA) Guidance on Treating Antimicrobial Resistant Gram-negativ...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Adis, Springer Healthcare
2025-06-01
|
| Series: | Infectious Diseases and Therapy |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s40121-025-01170-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849234868186120192 |
|---|---|
| author | Mohammed Al Musawa Ashlan J. Kunz Coyne Sara Alosaimy Kristen Lucas Melanie Rae Schrack Justin Andrade Shelbye R. Herbin Mark Biagi Michael Pierce Kyle C. Molina Nicholson B. Perkins Reese Cosimi Lena Kang-Birken Madeline A. King Benjamin M. Pullinger Leonor M. Rojas Jeannette Bouchard Athena L. V. Hobbs Jazmin Agee Kaylee E. Caniff Sean R. Van Helden Michael P. Veve Michael J. Rybak |
| author_facet | Mohammed Al Musawa Ashlan J. Kunz Coyne Sara Alosaimy Kristen Lucas Melanie Rae Schrack Justin Andrade Shelbye R. Herbin Mark Biagi Michael Pierce Kyle C. Molina Nicholson B. Perkins Reese Cosimi Lena Kang-Birken Madeline A. King Benjamin M. Pullinger Leonor M. Rojas Jeannette Bouchard Athena L. V. Hobbs Jazmin Agee Kaylee E. Caniff Sean R. Van Helden Michael P. Veve Michael J. Rybak |
| author_sort | Mohammed Al Musawa |
| collection | DOAJ |
| description | Abstract Introduction Stenotrophomonas maltophilia is notable for its rising incidence and multidrug resistance, which complicates treatment. As a result of insufficient clinical studies, the 2024 Infectious Diseases Society of America (IDSA) Guidance on Treating Antimicrobial Resistant Gram-negative Infection advises against using eravacycline (ERV) for S. maltophilia infections. We present real-world data on patients treated with ERV for these infections. Methods This multicenter, retrospective, observational study included adult patients who received ERV for treating S. maltophilia infections for ≥ 72 h between October 2018 and August 2022. The primary outcome was the clinical cure evaluated at the end of ERV therapy. Key secondary outcomes included a 30-day survival rate, absence of infection recurrence counting from the end of ERV therapy, and occurrence of possible ERV-related adverse effects (AE) noted in the patient’s records. Results Overall, 41 patients were included with a median (interquartile range [IQR]) age of 63 years (46.0–74.5). Most patients were male (63.4%) and white (51.2%). The primary source of infection was pulmonary (56.1%), and most patients received ERV for regimen consolidation (65.9%). Combination therapy was used in about 10% of the cases for S. maltophilia treatment. The median (IQR) duration of ERV treatment was 7 days (4.0–11.5). The clinical cure rate was 73.2%, and the 30-day survival rate was 68.3%. Four patients (9.8%) experienced possible AE from ERV. Conclusion S. maltophilia infections are challenging to treat because of limited options. An analysis of 41 patients indicates ERV may be an acceptable treatment option, but more clinical studies are needed to evaluate its efficacy and safety. |
| format | Article |
| id | doaj-art-7eee3fa917704a5f91f4a8d16303bb54 |
| institution | Kabale University |
| issn | 2193-8229 2193-6382 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Adis, Springer Healthcare |
| record_format | Article |
| series | Infectious Diseases and Therapy |
| spelling | doaj-art-7eee3fa917704a5f91f4a8d16303bb542025-08-20T04:03:00ZengAdis, Springer HealthcareInfectious Diseases and Therapy2193-82292193-63822025-06-011471499151110.1007/s40121-025-01170-xClinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia InfectionsMohammed Al Musawa0Ashlan J. Kunz Coyne1Sara Alosaimy2Kristen Lucas3Melanie Rae Schrack4Justin Andrade5Shelbye R. Herbin6Mark Biagi7Michael Pierce8Kyle C. Molina9Nicholson B. Perkins10Reese Cosimi11Lena Kang-Birken12Madeline A. King13Benjamin M. Pullinger14Leonor M. Rojas15Jeannette Bouchard16Athena L. V. Hobbs17Jazmin Agee18Kaylee E. Caniff19Sean R. Van Helden20Michael P. Veve21Michael J. Rybak22Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityOur Lady of the Lake Regional Medical CenterTouro College of Pharmacy, The Brooklyn Hospital CenterJohn D. Dingell VA Medical CenterUW Health Swedish American HospitalUW Health Swedish American HospitalDepartment of Emergency Medicine, University of Colorado Anschutz Medical CampusMethodist University HospitalAscension St. Vincent HospitalSanta Barbara Cottage HospitalPhiladelphia College of Pharmacy, Saint Joseph’s UniversityPhiladelphia College of Pharmacy, Saint Joseph’s UniversityValley Hospital Medical CenterCollege of Pharmacy, University of South CarolinaMethodist University HospitalMethodist University HospitalAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityEugene Applebaum College of Pharmacy and Health SciencesAnti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State UniversityAbstract Introduction Stenotrophomonas maltophilia is notable for its rising incidence and multidrug resistance, which complicates treatment. As a result of insufficient clinical studies, the 2024 Infectious Diseases Society of America (IDSA) Guidance on Treating Antimicrobial Resistant Gram-negative Infection advises against using eravacycline (ERV) for S. maltophilia infections. We present real-world data on patients treated with ERV for these infections. Methods This multicenter, retrospective, observational study included adult patients who received ERV for treating S. maltophilia infections for ≥ 72 h between October 2018 and August 2022. The primary outcome was the clinical cure evaluated at the end of ERV therapy. Key secondary outcomes included a 30-day survival rate, absence of infection recurrence counting from the end of ERV therapy, and occurrence of possible ERV-related adverse effects (AE) noted in the patient’s records. Results Overall, 41 patients were included with a median (interquartile range [IQR]) age of 63 years (46.0–74.5). Most patients were male (63.4%) and white (51.2%). The primary source of infection was pulmonary (56.1%), and most patients received ERV for regimen consolidation (65.9%). Combination therapy was used in about 10% of the cases for S. maltophilia treatment. The median (IQR) duration of ERV treatment was 7 days (4.0–11.5). The clinical cure rate was 73.2%, and the 30-day survival rate was 68.3%. Four patients (9.8%) experienced possible AE from ERV. Conclusion S. maltophilia infections are challenging to treat because of limited options. An analysis of 41 patients indicates ERV may be an acceptable treatment option, but more clinical studies are needed to evaluate its efficacy and safety.https://doi.org/10.1007/s40121-025-01170-xAntimicrobial resistanceDrug resistanceEravacyclineGram-negativeStenotrophomonas maltophilia |
| spellingShingle | Mohammed Al Musawa Ashlan J. Kunz Coyne Sara Alosaimy Kristen Lucas Melanie Rae Schrack Justin Andrade Shelbye R. Herbin Mark Biagi Michael Pierce Kyle C. Molina Nicholson B. Perkins Reese Cosimi Lena Kang-Birken Madeline A. King Benjamin M. Pullinger Leonor M. Rojas Jeannette Bouchard Athena L. V. Hobbs Jazmin Agee Kaylee E. Caniff Sean R. Van Helden Michael P. Veve Michael J. Rybak Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections Infectious Diseases and Therapy Antimicrobial resistance Drug resistance Eravacycline Gram-negative Stenotrophomonas maltophilia |
| title | Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections |
| title_full | Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections |
| title_fullStr | Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections |
| title_full_unstemmed | Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections |
| title_short | Clinical Outcomes of Eravacycline in Patients Treated for Stenotrophomonas maltophilia Infections |
| title_sort | clinical outcomes of eravacycline in patients treated for stenotrophomonas maltophilia infections |
| topic | Antimicrobial resistance Drug resistance Eravacycline Gram-negative Stenotrophomonas maltophilia |
| url | https://doi.org/10.1007/s40121-025-01170-x |
| work_keys_str_mv | AT mohammedalmusawa clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT ashlanjkunzcoyne clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT saraalosaimy clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT kristenlucas clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT melanieraeschrack clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT justinandrade clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT shelbyerherbin clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT markbiagi clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT michaelpierce clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT kylecmolina clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT nicholsonbperkins clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT reesecosimi clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT lenakangbirken clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT madelineaking clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT benjaminmpullinger clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT leonormrojas clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT jeannettebouchard clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT athenalvhobbs clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT jazminagee clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT kayleeecaniff clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT seanrvanhelden clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT michaelpveve clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections AT michaeljrybak clinicaloutcomesoferavacyclineinpatientstreatedforstenotrophomonasmaltophiliainfections |